Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Subscribe|Follow Us On    

Arginine Rewires eIF4F Translation Initiation to Overcome Fever-Induced CAR T Cell Dysfunction

[Cell Metabolism] In a retrospective cohort of patients with B cell acute lymphoblastic leukemia treated with CD22-directed CAR T cells, sustained high-grade fever inversely correlated with clinical response.

Niche-Reprogramming CAR T Therapy Improves Skeletal Muscle Regeneration and Function in Preclinical Murine Models of Duchenne Muscular Dystrophy

[Cell Stem Cell] Researchers identified urokinase plasminogen activator receptor as a shared surface marker on subsets of macrophages and fibro-adipogenic progenitors exhibiting strong pro-inflammatory and fibrogenic signatures in Duchenne muscular dystrophy.

Regulatable Membrane-Bound IL-15 Engineered TIL Cell Therapy for Immune Checkpoint Inhibitor-Resistant Advanced Melanoma: Pooled Analysis of Phase I and I/II Trials

[Nature Medicine] Scientists reported results from a completed first-in-human single-center Phase 1 trial and an ongoing Phase I/II multicenter trial of amsokigene autoleucel, a TIL cell therapy in patients with advanced melanoma progressing after immune checkpoint inhibitor therapy.

Anti-GD2 CAR T Cells Efficiently Target Ewing’s Sarcoma

[Cell Death & Disease] Investigators explored the therapeutic potential of GD2 CAR T cells in Ewing’s sarcoma, a disease for which effective treatment options remain a significant unmet medical need.

Cell Therapy and Autoimmune Diseases: Application Prospects and Challenges

[Expert Reviews in Molecular Medicine] The authors summarize current cell-based therapeutic strategies, their clinical applications, and the key challenges in the context of autoimmune diseases.

In Situ CAR Engineering and Nanoparticle-Mediated TREM2 Degradation for Macrophage Reprogramming in Malignant Ascites

[Nature Materials] Researchers developed lipid nanoparticles encapsulating mRNA to reprogram tumour-associated macrophages into CAR macrophages targeting Claudin18.2-positive tumour ascites.

Clonal Hematopoiesis and Cytopenias Following CAR19 Therapy

[Nature Genetics] Scientists studied patients with lymphoma receiving CAR19 and compared clinical outcomes to propensity-matched autologous hematopoietic cell transplantation-treated controls. CAR19-treated patients exhibited impaired immune reconstitution and increased infection.

CAR T and NK Cell Therapy for Acute Myeloid Leukemia

[International Immunology] Scientists summarize the current status of acute myeloid leukemia (AML) therapy, discuss the challenges of identifying suitable CAR targets, and introduces CAR T- and CAR natural killer-cell strategies targeting mismatched HLA-DRB1 molecules for treating relapsed AML after allogeneic hematopoietic cell transplantation.

Spatiotemporal Control of CAR-T Cell TNF Release via Tumor-Targeted Irradiation

[Nature Cancer] The authors showed that integrating the spatial precision of ionizing radiation with the biological specificity of CAR-T cells enables localized delivery of the inflammatory cytokine tumor necrosis factor (TNF).

Elicera Therapeutics Co-Founder Receives Grant Totaling SEK 4 Million from the Swedish Research Council for Research on CAR-T Cells against Solid Tumors

[Elicera Therapeutics ] Elicera Therapeutics announced that the company’s co-founder, Dr. Di Yu, has been awarded a grant from the Swedish Research Council. The four-year research project aims to increase knowledge of how CAR-T cells should be designed to persist longer in the body and more easily penetrate solid tumors.

Alex’s Lemonade Stand Foundation Funds 12 New Innovative Pediatric Cancer Grants

[Alex’s Lemonade Stand Foundation for Childhood Cancer] Alex’s Lemonade Stand Foundation has funded 12 Innovation Grants to help researchers pursue bold ideas that could change the future of childhood cancer. Across these 12 projects, researchers are exploring new ways to overcome treatment resistance, detect disease earlier, and uncover vulnerabilities that could lead to new therapies.

Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial

[Anixa Biosciences, Inc. (BioSpace)] Anixa Biosciences, Inc. announced that it has completed dosing of the fifth cohort in its ongoing Phase I, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.

spot_img